Vintafolide Drug Asset Due Diligence Report 2026

This Vintafolide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Vintafolide can convert its Small molecule-drug conjugates profile and FOLR1 x Tubulin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Vintafolide (query alias: Vintafolide)
Modality / target	Small molecule-drug conjugates; FOLR1 x Tubulin; FOLR1 antagonists, Tubulin inhibitors
Highest global status	Phase 2
Originator	Novartis Pharma AG
Active developers	Merck Sharp & Dohme Corp.

The MCP disease footprint includes Non-Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT2080222451	Phase 1	Status not available in English source	18	Primary endpoint not disclosed in English source
NCT02049281	Phase 1	Terminated	3	Primary endpoint not disclosed in English source
NCT01953536	Phase 2	Withdrawn	0	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Real-time identification of tumor lesions and response to vintafolide treatment.

Phase 2; n=44; evaluation: Not stated in English source. Reported fields: Sensitivity = 100 %

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).

Phase 2; n=49; evaluation: Not stated in English source. Reported fields: Lesion DCR = 56.4 % ; Lesion DCR = 20.7 %

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

Phase 2; n=149; evaluation: Positive. Reported fields: mPFS = 5.0 Month ; mPFS = 2.7 Month

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Vintafolide addresses Non-Small Cell Lung Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule-drug conjugates—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2014-06-01	Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)	Phase 3	US$120.0M upfront; US$880.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor combinations and uses thereof”. The milestone feed surfaced a patent-application signal described as “Peptides comprising N-formyl-halomethionine residues and engineered antibody-peptide conjugates thereof”. The milestone feed surfaced a patent-application signal described as “Anti-PD-1 antibodies and methods of making and using thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO